CellSeed Inc. (7776.T)
JPY 551.0
(0.0%)
JPY 551.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 301.04 Million JPY | -17.65% |
| 2022 | 365.58 Million JPY | 0.55% |
| 2021 | 363.58 Million JPY | 29.81% |
| 2020 | 280.08 Million JPY | 154.62% |
| 2019 | 110 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 310.6 Million JPY | 6.86% |
| 2024 Q1 | 290.65 Million JPY | -3.45% |
| 2023 Q2 | 362.63 Million JPY | -9.19% |
| 2023 Q4 | 301.04 Million JPY | -22.73% |
| 2023 Q1 | 399.32 Million JPY | 9.23% |
| 2023 FY | 301.04 Million JPY | -17.65% |
| 2023 Q3 | 389.59 Million JPY | 7.43% |
| 2022 Q3 | 400.88 Million JPY | 0.0% |
| 2022 FY | 365.58 Million JPY | 0.55% |
| 2022 Q4 | 365.58 Million JPY | -8.81% |
| 2021 FY | 363.58 Million JPY | 29.81% |
| 2020 FY | 280.08 Million JPY | 154.62% |
| 2019 FY | - JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 90.728% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -374.755% |
| GNI Group Ltd. | 26.34 Billion JPY | 98.857% |
| Linical Co., Ltd. | 10.3 Billion JPY | 97.079% |
| Trans Genic Inc. | 3.81 Billion JPY | 92.104% |
| MEDINET Co., Ltd. | 590.2 Million JPY | 48.993% |
| Soiken Holdings Inc. | 697.02 Million JPY | 56.81% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 90.034% |
| AnGes, Inc. | 2.78 Billion JPY | 89.207% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | 41.386% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.667% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | 14.783% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 81.754% |
| Carna Biosciences, Inc. | 472.35 Million JPY | 36.267% |
| CanBas Co., Ltd. | 91.98 Million JPY | -227.268% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 72.472% |
| RaQualia Pharma Inc. | 809.83 Million JPY | 62.826% |
| Chiome Bioscience Inc. | 593.73 Million JPY | 49.296% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 92.923% |
| PeptiDream Inc. | 29.11 Billion JPY | 98.966% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | 46.858% |
| Ribomic Inc. | 155.8 Million JPY | -93.215% |
| SanBio Company Limited | 2.25 Billion JPY | 86.649% |
| Healios K.K. | 11.28 Billion JPY | 97.333% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -19.811% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | 18.415% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -24.659% |
| StemRIM | 187 Million JPY | -60.988% |
| CellSource Co., Ltd. | 677.73 Million JPY | 55.581% |
| FunPep Company Limited | 189.32 Million JPY | -59.012% |
| Kringle Pharma, Inc. | 596.95 Million JPY | 49.57% |
| Stella Pharma Corporation | 1.44 Billion JPY | 79.146% |
| TMS Co., Ltd. | 97.68 Million JPY | -208.169% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -229.035% |
| Cuorips Inc. | 200.96 Million JPY | -49.804% |
| K Pharma,Inc. | 209.13 Million JPY | -43.949% |
| Takara Bio Inc. | 11.42 Billion JPY | 97.364% |
| ReproCELL Incorporated | 741.03 Million JPY | 59.375% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 67.196% |
| StemCell Institute Inc. | 3.85 Billion JPY | 92.182% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 66.861% |